share_log

Mangoceuticals | 10-Q: Q2 2024 Earnings Report

Mangoceuticals | 10-Q: Q2 2024 Earnings Report

Mangoceuticals | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/14 17:20

Moomoo AI 已提取核心訊息

Mangoceuticals reported Q2 2024 revenue of $163,163, up 15.5% year-over-year, driven by increased digital marketing efforts and recurring customer subscriptions. Gross profit was $69,792, down from $87,130 in Q2 2023 due to higher shipping costs and promotional discounts. Cost of revenues increased to $93,371 from $54,107 last year, correlating with higher product sales.Operating expenses totaled $2.24 million, with significant investments in legal fees of $165,368, software development of $239,520, and stock-based compensation of $859,380. Marketing expenses decreased to $229,244 from $797,263 last year as the company optimized its advertising strategy. General and administrative expenses rose to $850,704 from $567,655 in Q2 2023.The company ended the quarter with $490,243 in cash and reported a net loss of $2.39 million compared to $2.28 million in Q2 2023. Management secured additional funding through preferred stock offerings and equity purchase agreements to support operations and growth initiatives. The company also acquired key patents related to infection prevention technologies for $20 million through a combination of preferred stock and cash payments.
Mangoceuticals reported Q2 2024 revenue of $163,163, up 15.5% year-over-year, driven by increased digital marketing efforts and recurring customer subscriptions. Gross profit was $69,792, down from $87,130 in Q2 2023 due to higher shipping costs and promotional discounts. Cost of revenues increased to $93,371 from $54,107 last year, correlating with higher product sales.Operating expenses totaled $2.24 million, with significant investments in legal fees of $165,368, software development of $239,520, and stock-based compensation of $859,380. Marketing expenses decreased to $229,244 from $797,263 last year as the company optimized its advertising strategy. General and administrative expenses rose to $850,704 from $567,655 in Q2 2023.The company ended the quarter with $490,243 in cash and reported a net loss of $2.39 million compared to $2.28 million in Q2 2023. Management secured additional funding through preferred stock offerings and equity purchase agreements to support operations and growth initiatives. The company also acquired key patents related to infection prevention technologies for $20 million through a combination of preferred stock and cash payments.
Mangoceuticals報告2024年第二季度營業收入爲163,163美元，同比增長15.5%， driven by增加的數字營銷力度和重複客戶訂閱。毛利潤爲69,792美元，低於2023年第二季度的87,130美元，因交通成本和促銷折扣上升。營業收入成本從去年的54,107美元增加到93,371美元，與產品銷售的增長相關。營業費用總計224萬，法律費用165,368美元、軟件開發239,520美元和基於股票的補償859,380美元的投資佔比重。由於公司優化了廣告策略，營銷費用從去年的797,263美元降低至229,244美元。2023年第二季度的綜合管理費用從567,655美元上升至85...展開全部
Mangoceuticals報告2024年第二季度營業收入爲163,163美元，同比增長15.5%， driven by增加的數字營銷力度和重複客戶訂閱。毛利潤爲69,792美元，低於2023年第二季度的87,130美元，因交通成本和促銷折扣上升。營業收入成本從去年的54,107美元增加到93,371美元，與產品銷售的增長相關。營業費用總計224萬，法律費用165,368美元、軟件開發239,520美元和基於股票的補償859,380美元的投資佔比重。由於公司優化了廣告策略，營銷費用從去年的797,263美元降低至229,244美元。2023年第二季度的綜合管理費用從567,655美元上升至850,704美元。公司以490,243美元的現金結束了這一季度，並報告了239萬的淨虧損，相比之下，2023年第二季度爲228萬。管理層通過優先股發行和股權購買協議獲得額外資金，以支持營業費用和增長計劃。公司還以2,000萬的價格通過優先股和現金支付收購了與感染預防技術相關的關鍵專利。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    LifeMD
    LFMD
    -- 5.330
    Claritev
    CTEV
    -- 19.270
    TruBridge
    TBRG
    -- 30.100
    Forian
    FORA
    -- 2.120
    VSee Health
    VSEE
    -- 1.260
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    兩會召開：中概股走勢將如何演變？
    🎙️討論 1. 在政府強調科技創新和可持續發展的背景下，你認為哪些行業具有最大的增長潜力？ 2. 你預計“兩會”期間出臺的政策將如何影響你的投資策略？ 3. 你對“兩會”期間股市的波動性有何預期？ 展开
    中國兩會：會議前後股票價格變動的關鍵要點